Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease
Status:
Recruiting
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
Patients suffering of Parkinson's Disease will be treated with 50 mg/day of Safinamide per os
for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if
tolerated, the treatment will be taken for 10 more weeks (maintenance phase). Total treatment
12 weeks.